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httpOptimal selection of patients for elective abdominal
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William P. Robinson, MD,b Alik Farber, MD,c Virendra I. Patel, MD,d David H. Stone, MD,a and
Jack L. Cronewett, MD,a for the Vascular Study Group of New England, Lebanon, NH; and Worcester and
Boston, Mass
Objective: Elective abdominal aortic aneurysm (AAA) repair is beneﬁcial when rupture is likely during a patient’s expected
lifetime. The purpose of this study was to identify predictors of long-term mortality after elective AAA repair for
moderately sized AAAs (<6.5-cm diameter) to identify patients unlikely to beneﬁt from surgery.
Methods: We analyzed 2367 elective infrarenal AAA (<6.5 cm) repairs across 21 centers in New England from 2003 to
2011. Our main outcome measure was 5-year life-table survival. Cox proportional hazards analysis was used to describe
associations between patient characteristics and 5-year survival.
Results: During the study period, 1653 endovascular AAA repairs and 714 open AAA repairs were performed. Overall,
5-year survival rates were similar by procedure type (75% endovascular repair, 80% open repair; P [ .14). Advanced
age $75 years (hazard ratio [HR], 2.0; P < .01) and age >80 years (HR, 2.6; P < .01), coronary artery disease (HR, 1.4;
P < .04), unstable angina or recent myocardial infarction (HR, 4.6; P < .01), oxygen-dependent chronic obstructive
pulmonary disease (HR, 2.7; P < .01), and estimated glomerular ﬁltration rate <30 mL/min/1.73 m2 (HR, 2.8; P < .01)
were associated with poor survival. Aspirin (HR, 0.8; P < .03) and statin (HR, 0.7; P < .01) use were associated with
improved survival. We used these risk factors to develop risk strata for low-risk, medium-risk, and high-risk groups with
survival, respectively, of 85%, 69%, and 43% at 5 years (P < .001).
Conclusions:More than 75% of patients with moderately sized AAAs who underwent elective repair in our region survived
5 years, but 4% were at high risk for 5-year mortality. Patients with multiple risk factors, especially age >80 years, unstable
angina, oxygen-dependent chronic obstructive pulmonary disease, and estimated glomerular ﬁltration rate <30 mL/min/
1.73 m2, are unlikely to achieve sufﬁcient long-term survival to beneﬁt from surgery, unless their AAA rupture risk is very
high. (J Vasc Surg 2013;58:589-95.)Current treatment guidelines recommend that abdom-
inal aortic aneurysm (AAA) repair should be considered
when the maximum infrarenal aortic diameter reaches 5.5
cm.1 This threshold assumes that the annual risk of rupture
exceeds the operative mortality risk and that the patient will
otherwise survive long enough to overcome the up-front
risk of surgical treatment. Although operative mortality
and AAA rupture risk have been studied extensively, less
is known about long-term survival after AAA repair, partic-
ularly in high-risk patients. Screening programs may iden-
tify AAA patients at the threshold for repair,2 but patientsthe Section of Vascular Surgery, Dartmouth-Hitchcock Medical
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with other life-limiting comorbidities.3 Thus, some high-
risk patients with 5.5-cm AAAs might die from other
causes if their AAA is not repaired and not gain substantial
additional life expectancy from AAA repair.4
The purpose of the present study was to identify
patient risk factors associated with poor long-term survival
after elective AAA repair by using data from the Vascular
Study Group of New England (VSGNE) regional multi-
center vascular registry. This information could then be
used to optimally select patients who would most likely
live long enough to beneﬁt from elective AAA repair.
METHODS
Patients and database. This is a retrospective analysis
of data collected prospectively by the VSGNE, a regional
cooperative quality improvement initiative developed in
2002 to study regional outcomes in vascular surgery.5 Of
note, registry data are compared with hospital claims in
regular audits, and missing cases are retrieved to yield
a nearly complete capture rate (>99%) to limit reporting
biases.5 The Social Security Death Index was used to
determine mortality status for all patients up to June 1,
2011. No patients were lost to follow-up for survival
analysis. Although not all outcome events are audited,
there is no beneﬁt to under-reporting, given that reporting
is anonymous.589
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AAAs with diameters <6.5 cm by 97 participating surgeons
in 21 study hospitals from 2003 to 2011 were included in
the analysis. Emergency repair for rupture or urgent repairs
within #24 hours of admission for symptoms were
excluded. We only included open AAA repairs (OAR) if
an infrarenal clamp location was used or endovascular
AAA repairs (EVAR) that were for an infrarenal AAA,
without the use of advanced techniques such as snorkels.
We excluded patients with AAA diameters $6.5 cm
(by any preoperative imaging modality) because this size
represents high rupture risk (>30% per year) and these
patients almost always need repair. However, the rupture
risk of patients with AAA diameters <6.5 cm was deemed
moderate (<10% per year), so that an operating surgeon
could use risk-stratiﬁcation to decide whether to repair
the AAA or manage it medically until the AAA expanded
further.6
Prior studies have shown similar long-term survival for
EVAR and OAR.7-9 Thus, we planned to combine these
cohorts if our analysis determined that survival was not
different between these groups in our region. We did not
exclude perioperative deaths because this might have
biased survival estimates for the most severe life-limiting
conditions that can result in death shortly after repair.
Five-year survival was determined from the VSGNE data-
base and by matching patient information with the Social
Security Death Index.
Medication use was deﬁned as taking aspirin or statin
(3-hydroxy-3-methylglutaryl-coenzyme A reductase inhib-
itor) preoperatively. Deﬁnitions of medical comorbidities in
the VSGNE cohort have been previously published.10
Data collection and statistical analysis. Physicians,
nurses, or clinical data abstractors entered data prospec-
tively on clinical and demographic variables. Research
analysts were blinded to patient, surgeon, and hospital
identity. The Committee for the Protection of Human
Subjects at Dartmouth Medical School approved the use
of deidentiﬁed data from VSGNE for research purposes.
Preoperative variables were compared between OAR
and EVAR using c2 for categoric variables with Fisher exact
correction as indicated. A two-sample t-test or Wilcoxon
rank sum test was used to compare parametric or nonpara-
metric continuous variables, respectively. For survival anal-
ysis, univariate comparisons were made with log-rank for
categoric variables or Cox proportional hazards for contin-
uous variables. Variables of clinical signiﬁcance and those
with a value of P < .1 by univariate survival analysis were
included in a backwards stepwise multivariate Cox propor-
tional hazards model to identify signiﬁcant predictors of
5-year mortality. Schoenfeld residuals were analyzed to
ensure the proportional hazards assumptions were not
violated for variables associated with 5-year mortality.
Variables were removed using the likelihood ratio test.
Continuous variables with nonlinear risk were catego-
rized for analysis. Age was categorized by quartiles. The
b-coefﬁcients for each signiﬁcant variable were divided by
a common denominator, resulting in a numeric point scalefor each risk factor that could be summed to create a risk
score.11 Variables were designated as major or minor risk
factors by their relative number of points (1-2 points vs
3-4 points, respectively) for creation of risk strata for anal-
ysis. Values of P < .05 were considered signiﬁcant.
RESULTS
Patient demographics and overall survival. During
the study period, 4050 aneurysm repairs were performed;
of these, 438 patients were excluded for rupture, 271 for
symptomatic AAA, 401 for suprarenal clamp, and 573 for
an AAA >6.5 cm. This resulted in 2367 elective repairs
of infrarenal AAAs <6.5 cm in diameter for analysis. Of
these, 1653 (70%) were by EVAR and 714 (30%) were
by OAR. Patient demographics are presented in Table I.
Overall, EVAR patients were slightly older than OAR
patients (72.4 vs 69.3 years; P < .001) and were more
likely to be men (79.4% vs 72.8%; P < .001) and have
higher rates of smoking, diabetes, and congestive heart
failure (Table I). Patients undergoing EVAR were less
likely to have preoperative echocardiography. However,
when only those who had echocardiograms were
compared, EVAR patients were more likely to have an
ejection fraction <50% (24.7% vs 15.2%; P < .001).
Similarly, although EVAR patients were less likely to have
preoperative stress testing, when only those with stress test
results were compared, EVAR patients had higher rates of
abnormal stress test results (30.8% vs 23.6%; P ¼ .004).
Although overall rates of chronic obstructive pulmonary
disease (COPD) were similar between EVAR and OAR,
EVAR patients had higher rates of advanced COPD
(Table I). Prior AAA repair and use of aspirin, clopidogrel,
and statin were similar, but b-blocker use was higher in
patients undergoing OAR.
In-hospital mortality for the entire cohort was 1%
(OAR, 1.8%; EVAR, 0.67%; P ¼ .01). Survival for the
entire cohort at 5 years was 77% (95% conﬁdence interval
[CI], 75%-80%). Average follow-up was 2.4 years (inter-
quartile range [IQR], 0.9-4.6 years), with median follow-
up of 1.9 years for EVAR (IQR, 0.75-4 years) compared
with 3.6 years for OAR (IQR, 1.6-5.7 years) due to
increased EVAR use in later years. Despite the apparent
demographic differences between EVAR and OAR
patients, they had similar 5-year survival (Fig 1) of 75%
for EVAR (95% CI, 72%-78%) and 80% for OAR (95%
CI, 76%-83%; log-rank ¼ 0.17).
Multivariable predictors of 5-year mortality. In-
creasing age, particularly from age 75 to 79 (hazard ratio
[HR], 2.0; 95% CI, 1.4-2.8) and age >80 years were
associated with worse 5-year survival (HR, 2.6; 95%
CI, 1.8-3.7; Table II), as expected. In addition, prior
myocardial infarction (MI), stable angina, and recent MI or
unstable angina were signiﬁcantly associated with worse
5-year survival (Table II). Lastly, oxygen-dependent
COPD (HR, 3.0; 95% CI, 2.0-4.5) and estimated
glomerular ﬁltration rate (eGFR) <30 mL/min/1.73 m2
(HR, 3.0; 95% CI, 1.9-4.7) were associated with worse
survival. Preoperative aspirin and statin use were associated
Table I. Patient demographics
Variablea
All patients
(N ¼ 2367)
EVAR
(n ¼ 1653)
OAR
(n ¼ 714) Pb
Age, years 72 (8.4) 73.4 (8.1) 69.3 (8.4) <.001
Max AAA diameter, mm 53.6 (6.4) 53.8 (6.2) 53.3 (6.8) .089
Male sex 77.4 79.4 72.8 <.001
Any smoking history 88.3 86.3 92.8 <.001
Hypertension 83.7 84.4 82.2 .182
Diabetes 18.7 20.5 14.6 .001
Coronary artery disease 33.8 34.8 31.4 .114
Prior coronary revascularization 30.2 30.4 29.6 .715
Congestive heart failure 8.0 9.9 3.7 <.001
Ejection fraction, %
<30 2.0 2.4 1.0 <.001
30-50 10.8 10.8 10.7
>50 47.7 40.1 65.3
Not done 36.9 43.5 21.5
Unknown 2.7 3.2 1.6
COPD
No 66.0 65.7 66.5 .009
Yes, untreated 14.2 13.1 16.6
Yes, on medication 15.8 16.3 14.5
On home oxygen 4.1 4.8 2.5
eGFR, mL/min/1.73 m2
$60 65.3 64.8 66.5 .53
40-59 25.0 25.7 23.3
30-39 7.2 7.3 7.2
<30 2.5 2.4 3.0
Stress testing
Not done 45.3 55.5 21.7 <.001
Normal result 39.6 30.8 59.8
Abnormal result 15.2 13.7 18.5
Prior AAA repair 2.3 2.5 1.7 .199
Medication use
Aspirin 72.6 72.7 72.5 .773
Clopidogrel 6.1 6.6 4.9 .148
Statin 69.2 70.0 67.2 .117
b-Blocker 78.8 76.3 84.7 <.001
AAA, Abdominal aortic aneurysm; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular ﬁltration rate; EVAR, endovascular aneurysm
repair; OAR, open aneurysm repair.
aContinuous data are shown as mean (standard deviation) and categoric data as percentage.
bComparisons made between EVAR and OAR.
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OAR), aneurysm size (<5.5 vs 5.5-6.5 cm), and smoking
status (former or current) did not affect survival and were
not included in the ﬁnal model.
Identiﬁcation of risk strata for 5-year mortality.
From the results of our multivariable Cox model, we
identiﬁed nine independently signiﬁcant predictors of
5-year mortality (Table II). The b-coefﬁcients derived
from the relative contribution of each risk factor of the
Cox model were used to normalize risk factors to create
a risk score (Table III, A). The relative impact on 5-year
survival was greatest among those aged >80 years, recent
MI or unstable angina, oxygen-dependent COPD, and
eGFR <30 mL/min/1.73 m2, noted by their higher point
value. These risk factors were deemed major, whereas age
75-79 years, prior MI, stable angina, and lack of aspirin or
statin use were considered minor. Patients in our cohort
had zero (74%), one (24%), or two (2%) of these major risk
factors. Because these factors had the greatest impact,patients were stratiﬁed by the number of high-risk factors
or their minor risk-factor equivalent score. Speciﬁcally,
low-risk patients had zero major risk factors, but could have
two or fewer minor risk factors. Medium-risk patients had
one major risk factor or multiple minor risk factors, whereas
high-risk patients had to have two major risk factors or one
major risk factor and more than two minor risk factors
(Table III, B).
Using this method of categorizing patients, we identi-
ﬁed 1403 low-risk patients (61%), 824 medium-risk
patients (35%), and 83 high-risk patients (4%) within our
cohort. With increasing risk strata, patients were signiﬁ-
cantly older, were more likely to be female, have larger
aneurysms, to undergo EVAR, and to have higher rates
of cardiac, pulmonary, and renal disease. Higher-risk
patients were also less likely to be receiving statin or aspirin
therapy (Table IV). These groups demonstrated signiﬁ-
cantly different survival. Survival for low-risk, medium-
risk, and high-risk groups at 5 years was, respectively,
Table III. B, Designation of low-risk, medium-risk, and
high-risk patients for long-term mortality after abdominal
aortic aneurysm (AAA) repair
Risk Determined by
Low risk No major risk factors or
1-2 minor risk factors, or both
Medium risk 1 major risk factor or
3-4 minor risk factors
High risk 2 major risk factors or
1 major risk factor and $3 minor risk factors
Fig 1. Overall survival in patients after undergoing open or
endovascular abdominal aortic aneurysm repair (EVAR). SE,
Standard error.
Table II. Multivariable factors associated with long-term
mortality
Factor HR (95% CI) P
Age, years
<65 1.0 (Ref)
65-74 1.3 (0.9-1.9) .146
75-79 2.0 (1.4-2.8) <.001
$80 2.6 (1.8-3.7) <.001
Coronary artery disease
None 1.0 (Ref)
Prior MI 1.5 (1.2-1.9) .001
Stable angina 1.5 (1.0-2.0) .036
Unstable angina or recent MI 4.2 (1.7-10.3) .002
COPD
None 1.0 (Ref)
Not treated 1 (0.7-1.3) .855
On medication 1.3 (1.0-1.8) .055
On home oxygen 3.0 (2.0-4.5) <.001
eGFR, mL/min/1.73 m2
$60 1.0 (Ref)
40-59 1.2 (0.9-1.6) .1
30-39 1.4 (0.9-2.0) .09
<30 3.0 (1.9-4.7) <.001
Female sex 0.9 (0.7-1.2) .511
Aspirin use 0.8 (0.6-0.9) .023
Statin use 0.7 (0.6-0.9) .003
CI, Conﬁdence interval; COPD, chronic obstructive pulmonary disease;
eGFR, estimated glomerular ﬁltration rate; HR, hazard ratio; MI, myocar-
dial infarction; OR, odds ratio.
Table III. A, Risk factors for long-term mortality after
abdominal aortic aneurysm (AAA) repair
Criteria Points
Major criteria
Unstable angina or recent MI 4
Age $80 years 3
Oxygen-dependent COPD 3
eGFR <30 mL/min/1.73 m2 3
Minor criteria
Age 75-79 years 2
Prior MI 1
Stable angina 1
Not taking aspirin 1
Not taking statin 1
COPD, Chronic obstructive pulmonary disease; MI, myocardial infarction;
eGFR, estimated glomerular ﬁltration rate.
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43% (95% CI, 27%-57%; log rank <.001; Fig 2).
DISCUSSION
The preoperative evaluation of patients with AAA is
complex. The decision to treat a patient’s aneurysm is
based on a combination of the aneurysm size, morphology,and rupture risk in the context of the patient’s comorbid-
ities and expected beneﬁt from prophylactic repair. Pati-
ents with a high-anticipated rupture risk and favorable
comorbidity proﬁle are offered repair. However, those
with a limited life expectancy from major comorbidities
may not gain a survival beneﬁt from repair if their rupture
risk is low. We have identiﬁed patient factors that predict
poor 5-year survival after AAA repair to assist in patient
selection for intervention. It is clear from our analysis
that patients with advanced age, cardiac disease, COPD,
and renal disease have poor 5-year survival. These comor-
bidities are additive in their effect on mortality, such that
those with two or more of these risk factors will experience
only 50% survival at 5 years, despite repair.
Overall, our results demonstrate that the 5-year
survival after AAA repair in our region is very good.
EVAR and OAR patients experience a similar 5-year
survival of 80% and 75% at 5 years. Of all infrarenal AAA
repairs, only 4% were in patients deemed at high risk for
5-year mortality, suggesting appropriate patient selection
in our region. Our survival results are similar to contempo-
rary randomized trials (75% at 5 years)9 and are favorable
compared with historical series of AAA repair with 5-year
survival of 58% to 63%.12,13
In an early report of 25 years of OARs, Crawford
et al12 reported survival of 63% at 5 years postoperatively.
As in the present study, coronary disease and age were
Table IV. Characteristics of high-risk, medium-risk, and low-risk groups for long-term mortality after abdominal aortic
aneurysm (AAA) repair
Variablea
Low risk
(n ¼ 1403)
Medium risk
(n ¼ 824)
High risk
(n ¼ 83) Pb
Age, years 67.7 (6.3) 78.9 (5.9) 80 (4.7) <.001
Max AAA diameter, mm 5.3 (0.7) 5.5 (0.6) 5.6 (0.4) <.001
Male sex 81 72 63 <.001
EVAR 64 79 81 <.001
Smoking history 92 81 89 <.001
Coronary artery disease 29 40 52 <.001
Congestive heart failure 6 11 18 <.001
COPD 33 33 66 <.001
eGFR, mL/min/1.73 m2
$60 73.6 55.0 30.1 <.001
40-59 20.8 31.8 25.3
30-39 5.6 10.0 6.0
<30 0.0 3.2 38.6
Medication use
Aspirin 78 65 53 <.001
Statin 75 60 61 <.001
b-Blocker 80 77 75 .167
Diabetes 19 17 22 .338
COPD, Chronic obstructive pulmonary disease; eGFR, estimated glomerular ﬁltration rate; EVAR, endovascular aneurysm repair.
aContinuous variables are presented as mean (standard deviation) and categoric variables as percentage.
bComparisons made across all three strata. Analysis of variance for continuous and Pearson c2 for categorical variable analysis.
Fig 2. Risk strata for mortality after abdominal aortic aneurysm
(AAA) repair.
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advanced age and life-limiting comorbidities give pause to
otherwise proceeding with elective repair of AAA and that
improvement in long-term survival after OAR would be
a result of better patient selection.12,13 Debakey et al13
demonstrated similar ﬁndings. Survival was greatest in those
with no hypertension or cardiovascular disease (74% vs 51%)
at 5 years. In our series, survival was improved in those
without hypertension or coronary disease compared with
those with these conditions, but not to the extent of prior
reports (77% vs 82% at 5 years).13 This highlights the effect
on survival from other comorbid conditions, such as COPD
and renal disease, in contemporary practice.Two plausible explanations for our improved 5-year
survival after AAA repair compared with these prior historic
reports include better patient selection and improved peri-
operative and postoperative management. Surgeons in this
cohort may have avoided patients at high risk for subse-
quent early death from associated comorbidities. Because
we found that EVAR is more often applied to high-risk
patients, this may also be a differentiating factor compared
with these early reports of only OAR.
The second explanation is that perioperative and post-
discharge medical management has improved greatly in
recent decades. Overall trends for the past decade demon-
strated a decline in perioperative AAA repair mortality rates
in the United States14 and in other countries.15 This has
been greatly inﬂuenced by the lower perioperative
mortality rate of EVAR. In addition, the adoption of
evidence-based measures, such as perioperative b-blockade,
has been shown to reduce mortality after AAA repair.16
Furthermore, within the present study, preoperative
aspirin and statin use was associated with improved 5-year
survival. In VSGNE, 52% of patients were discharged with
both statin and antiplatelet therapy after AAA repair, which
is likely much higher than in historical comparison studies.
The use of aspirin in patients with atherosclerotic
disease for secondary and tertiary prevention of cardiovas-
cular events is well established.17,18 However, there are
no published data for a survival beneﬁt of aspirin therapy
in patients after AAA repair, and aspirin is not included
within the current Society for Vascular Surgery practice
guidelines for care of patients with AAA.1 A recent Danish
epidemiologic study demonstrated that AAA patients have
a higher incidence of cardiac and cerebrovascular events, as
well as overall mortality, compared with the general
JOURNAL OF VASCULAR SURGERY
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aspirin use may be due to prevention of cardiovascular
events in this high-risk population. This suggests that
the care of patients with AAA may be improved with
aspirin therapy as a secondary preventative strategy for
cardiovascular events.
In contrast, statin use is recommended as medical
management for patients with AAA.1,18 Our ﬁnding that sta-
tin use was associated with improved 5-year survival is consis-
tent with other reports.20 A recent meta-analysis of nearly
12,000 patients after AAA repair demonstrated a beneﬁcial
effect of statin use in long-term survival (HR, 0.57) up to
5 years.21 In contrast to age and other comorbid conditions,
aspirin and statin use represent a potentially modiﬁable risk
factor that can improve survival. In the context of the avail-
able evidence, our data are consistent with the hypothesis
that optimal cardiovascular medical management, including
aspirin and statin use in AAA patients, will improve survival
due to prevention of late cardiovascular events.
The present study has several limitations. Our analysis
is retrospective and based on patients selected for AAA
repair. Thus, a portion of high-risk AAA patients who
were not offered surgery is not represented. This is consis-
tent with our ﬁnding that only 4% of patients were “high-
risk.” The creation of disease-based registries, compared
with procedural-based registries, may offer the ability for
these types of comparisons in the future.
In addition, we sought to create a clinically relevant
method for risk stratiﬁcation of patients undergoing AAA
repair. This is based on the contribution of risk factors in
our multivariable model. Although our speciﬁc thresholds
for low risk, medium risk, or high risk may be open to
debate, our stratiﬁcation has clinical and face validity
because the major drivers of 5-year mortality have been
demonstrated previously. Our present stratiﬁcation system
for predicting 5-year survival provides an appropriate back-
ground for patient assessment and selection that must also
include assessment of risks and beneﬁts of repair. This will
include factors that may increase the risk of rupture, such as
the presence of COPD, as well as the adjustment of modiﬁ-
able risk factors to optimize survival after repair. Validation
of our survival risk score requires testing in additional
patients in the future.
CONCLUSIONS
These data suggest that survival after AAA repair is
good in contemporary practice and appears to be better
than in historical series. Factors such as advanced age,
cardiac disease, oxygen-dependent COPD, and an eGFR
<30 mg/mL/1.73 m2 are major risk factors associated
with 5-year mortality in patients undergoing AAA repair in
our region. Conversely, aspirin and statin use were associ-
ated with improved survival. Patients with very high comor-
bidity proﬁles may have<50% 5-year survival, and repair can
only be beneﬁcial if rupture risk is assessed as very high.
Efforts at improved medical management in patients after
AAA repair may improve survival by preventing cardiovas-
cular events.We thank Jens Eldrup-Jorgensen, MD, and Robert
Cambria, MD, for their contribution to the development
and revision of this manuscript.
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